Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
2002-07-31
2004-11-09
Salimi, Ali R. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
C424S231100, C424S186100, C435S006120, C435S091330, C536S023720
Reexamination Certificate
active
06814969
ABSTRACT:
TECHNICAL FIELD OF THE INVENTION
The invention relates to molecules, compositions and methods that can be used for the treatment and prevention of HSV infection. More particularly, the invention identifies epitopes of HSV proteins that can be used for methods, molecules and compositions having the antigenic specificity of HSV-specific T cells, and in particular, of CD8+ as well as CD4+ T cells.
BACKGROUND OF THE INVENTION
Cellular immune responses are required to limit the severity of recurrent HSV infection in humans. Initial genital HSV-2 infections are prolonged and severe, while recurrences are less severe and more frequently asymptomatic. Resolution of primary HSV-2 infection is associated with infiltration of antigen-specific T cells, including CD8+ cytotoxic T lymphocytes (CTLs). Serial lesion biopsy studies of recurrent HSV-2 infection in humans has shown a shift to CD8+ predominance as lesions mature and correlation of local CTL activity with virus clearance (Koelle, D M et al., J. Clin. Invest. 1998, 101:1500-1508; Cunningham, Ala. et al., J. Clin. Invest. 1985, 75:226-233). Thus, HSV antigens recognized by CD8+ CTL can be used for novel therapies and vaccines.
The complete DNA sequence of herpes simplex virus (HSV) is approximately 150 kb and encodes about 85 known genes, each of which encodes a protein in the range of 50-1000 amino acids in length. Unknown are the immunogenic epitopes within these proteins, each epitope approximately 9-12 amino acids in length, that are capable of eliciting an effective T cell immune response to viral infection.
There remains a need to identify specific epitopes capable of eliciting an effective immune response to HSV infection. Such information can lead to the identification of more effective immunogenic antigens useful for the prevention and treatment of HSV infection.
SUMMARY OF THE INVENTION
The invention provides HSV antigens, polypeptides comprising HSV antigens, polynucleotides encoding the polypeptides, vectors, and recombinant viruses containing the polynucleotides, antigen-presenting cells (APCs) presenting the polypeptides, immune cells directed against HSV, and pharmaceutical compositions. The pharmaceutical compositions can be used both prophylactically and therapeutically. The antigens of the invention are recognized by T cells recovered from herpetic lesions. The invention additionally provides methods, including methods for preventing and treating HSV infection, for killing HSV-infected cells, for inhibiting viral replication, for enhancing secretion of antiviral and/or immunomodulatory lymphokines, and for enhancing production of HSV-specific antibody. For preventing and treating HSV infection, for enhancing secretion of antiviral and/or immunomodulatory lymphokines, for enhancing production of HSV-specific antibody, and generally for stimulating and/or augmenting HSV-specific immunity, the method comprises administering to a subject a polypeptide, polynucleotide, recombinant virus, APC, immune cell or composition of the invention. The methods for killing HSV-infected cells and for inhibiting viral replication comprise contacting an HSV-infected cell with an immune cell of the invention. The immune cell of the invention is one that has been stimulated by an antigen of the invention or by an APC that presents an antigen of the invention. A method for producing such immune cells is also provided by the invention. The method comprises contacting an immune cell with an APC, preferably a dendritic cell, that has been modified to present an antigen of the invention. In a preferred embodiment, the immune cell is a T cell such as a CD4+ or CD8+ T cell.
In one embodiment, the invention provides a composition comprising an HSV polypeptide. In one embodiment, the polypeptide comprises a U
L
49 protein or a fragment thereof. In a preferred embodiment, the fragment of a U
L
49 protein comprises amino acids 14-22, 21-35, 45-59, 49-57, 49-63, 105-190, 177-220 or 193-208 of U
L
49 or a substitutional variant thereof. In another embodiment, the polypeptide comprises an ICP0 protein or a fragment thereof. In one embodiment, the fragment of an ICP0 protein comprises amino acids 92-101, 92-105, 288-307 or 743-751 of ICP0 or a substitutional variant thereof. In another embodiment, the polypeptide comprises a U
L
48 protein or a fragment thereof. In one embodiment, the fragment of a U
L
48 protein comprises amino acids 185-197, 209-221, 288-307 or 430-449 of VP16 (U
L
48) or a substitutional variant thereof.
Also provided is an isolated polynucleotide that encodes a polypeptide of the invention, and a composition comprising the polynucleotide. The invention additionally provides a recombinant virus genetically modified to express a polynucleotide of the invention, and a composition comprising the recombinant virus. In preferred embodiments, the virus is a vaccinia virus, canary pox virus, HSV, lentivirus, retrovirus or adenovirus. A composition of the invention can be a pharmaceutical composition. The composition can optionally comprise a pharmaceutically acceptable carrier and/or an adjuvant.
REFERENCES:
patent: 4859587 (1989-08-01), Roizman
patent: 5632992 (1997-05-01), Nesburn et al.
patent: 5714152 (1998-02-01), Burke et al.
patent: WO 92/02251 (1992-02-01), None
patent: WO 97/05265 (1997-02-01), None
patent: WO 00/08051 (2000-02-01), None
patent: WO 01/23414 (2001-05-01), None
Koelle, D.M., et al., “CD8 CTL from Genital Herpes Simplex Lesions: Recognition of Viral Tegument and Immediate Early Proteins and Lysis of Infected Cutancous Cells”,The Journal of Immunology, vol. 166 (6): 4049-4058, Mar. 2001.
E. De. Plaen et al., “Cloning of Genes Coding for Antigens Recognized by Cytolytic T Lymphocytes,” Immunology Methods Manual, 1997, 692-718.
A. Dolan et al., “The Genome Sequence of Herpes Simplex Virus Type 2,” Journal of Virology, 1998, 72(3):2010-2021.
G. Elliott and P. O'Hare, “Intercellular Trafficking and Protein Delivery by a Herpesvirus Structural Protein,” Cell, 1997, 88:223-233.
D.M. Koelle et al., “Antigenic Specificities of Human CD+T-Cell Clones Recovered from Recurrent Genital Herpes Simples Virus Type 2 Lesions,” Journal of Virology, 1994, 68(5):2803-2810.
D.M. Koelle et al., “Clearance of HSV-2 from Recurrent Genital Lesions Correlates with Infiltration of HSV-Specific Cytotoxic T Lymphoctyes,” The Journal of Clinical Investigation, 1998, 101(7):1500-1508.
D.M. Koelle et al., “Direct Recovery of Herpes Simplex Virus (HSV)-Specific T Lymphocyte Clones from Recurrent Genital HSV-2 Lesions,” The Journal of Infectious Diseases, 1994, 169:956-61.
D.M. Koelle et al., “Preferrential Presentation of Herpes Simplex Virus T-Cell Antigen by HLA DQA1*0501/DQB1*0201 in Comparison to HLA DQA1*0201/DQB1*0201,” Human Immunology, 1997, 53(2):195-205.
D.M. Koelle et al., “Recognition of Herpes Simplex Virus Type 2 Tegument Proteins by CD4 T Cells . . . ” Jnl. of Virology, 1998, 72(9): 7476-7483.
D.M. Koelle, “The Roles of T Lymphocytes in Host Responses to Herpes Simplex Virus,” Herpes, 1995, 2:83-88.
W.W. Kwok et al., “Peptide Binding Affinity and pH Variation Establish Functional Thresholds for Activation of HLA-DQ-Restricted T Cell Recognition,” Human Immunology, 1999, 60(7):619-626.
Paoletti, “Applications of Pox Virus Vectors to Vaccination: An Update,” Proceedings of the National Academy of Science USA, Oct. 1996, 93:11349-11353.
C.M. Posavad et al., “High Frequency of CD8+Cytotoxic T-Lymphoctye Precursors Specific for Herpes Simplex Viruses in Persons with Genital Herpes,” Journal of Virology, 1996, 70(11):8165-8168.
S. Reichstetter et al., “MCH-Peptide Ligand Interactions Establish a Functional Threshold for Antigen-Specific T Cell Recognition,” Human Immunology, 1999, 60(7):608-618.
B. Roizman et al., “Herpes Simplex Viruses and Their Replication”, Fundamental Virology, 2ndEdition, ed. Fields et al, Raven Press, 1991, New York, pp. 849-895.
Tatman, J.D. et al., “Assembly of Herpes Simplex Virus Type 1 Using a Panel of Recombinant Baculoviruses,” Journal of General Virology, 1
Chen Hongbo
Hosken Nancy A.
Koelle David M.
McGowan Patrick
Posavad Christine M.
Gates & Cooper LLP
Salimi Ali R.
University of Washington
LandOfFree
Immunologically significant herpes simplex virus antigens... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immunologically significant herpes simplex virus antigens..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunologically significant herpes simplex virus antigens... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3294137